To explore the effect of anti‐PD‐1 immunotherapy combined with chemotherapy on the gut microbiota of NSCLC patients, this study analyzed paired stool samples from 15 NSCLC patients before treatment (before group) and after treatment (after group). This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.